Vortioxetine for the Treatment of Depression

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

(2013) Grace Chen et al.   CLINICAL DRUG INVESTIGATION

A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition

(2013) E L Theunissen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder

(2013) Mohammed Y. Alam et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day

(2013) Jean-Philippe Boulenger et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2013) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010

(2013) Alize J. Ferrari et al.   PLOS MEDICINE

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

(2012) David S. Baldwin et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

(2012) Atul R. Mahableshwarkar et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

(2012) Rakesh Jain et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder

(2012) Neven Henigsberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

(2012) Jean-Philippe Boulenger et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects

(2011) Johan Areberg et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

(2011) David S. Baldwin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY